Brisk sales of Apple’s iPhone 14 Pro are expected to buoy related lens module makers’ sales performance in the second half of 2022, according to market sources.
NeuBase Therapeutics Reports Business Update And Financial Results For Q1 Of FY23; As Of December 31, 2022, The Company Had Cash And Cash Equivalents Of ~$17.4M
NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision
